McKesson — May 8, 2025 release

I want to thank Team McKesson for their hard work and dedication this past quarter and throughout fiscal 2025." "As we look ahead to fiscal 2026, we are well positioned to build on our operating momentum, accelerate growth through our strategic priorities, and target investments to accelerate growth and modernize the portfolio." Outlook: • Establishing fiscal 2026 Adjusted Earnings per Diluted Share guidance range of $36.75 to $37.55 which indicates 11% to 14% forecasted growth compared to the prior year. Excluding fiscal 2025 net gains associated with McKesson Ventures' equity investments, the guidance range indicates 13% to 16% forecasted growth. • The Company does not forecast GAAP earnings per diluted share 1 . • Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 12% to 14% and updating long-term Adjusted Segment Operating Profit growth target for U.S. Pharmaceutical from 5% to 7% to a new target of 6% to 8%. 1 See below under "Fiscal 2026 Outlook" for full explanation Strategic Portfolio Update for the Medical-Surgical Solutions Segment Today McKesson is announcing its intention to separate its Medical-Surgical Solutions segment into an independent company ("NewCo"). Disciplined portfolio management is a hallmark of our enterprise strategy. McKesson believes a separation will further enhance the strategic opportunity and operational focus of both companies and unlock value for McKesson shareholders. The separation would advance McKesson and NewCo's ability to create value for customers, partners, patients, and shareholders. With a separation of Medical-Surgical Solutions, McKesson will focus the Company and